16. Cervix cancer - The GEC-ESTRO Handbook of Brachytherapy

Cervix cancer

33

THE GEC ESTRO HANDBOOK OF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 01/09/2023

study. Radiother Oncol. 2016;118(1):160-6. 40. Mohamed S, Lindegaard JC, de Leeuw AA, et al. Vaginal dose de-escalation in image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2016;120(3):480-5. 41. Serban M, Fokdal L, Nielsen SK, et al. Characterization of combined intracavitary/ interstitial brachytherapy including oblique needles in locally advanced cervix cancer. Brachytherapy. 2021;20(4):796-806. 42. Kirisits C, Tanderup K, Hellebust T, et al. Physics for Image-Guided Brachytherapy. 2011. p. 143-64. 43. Jamema SV, Kirisits C, Mahantshetty U, et al. Comparison of DVH parameters and loading patterns of standard loading, manual and inverse optimization for intracavitary brachytherapy on a subset of tandem/ovoid cases. Radiother Oncol. 2010;97(3):501-6. 44. Nkiwane KS, Andersen E, Champoudry J, et al. Total reference air kerma can accurately predict isodose surface volumes in cervix cancer brachytherapy. A multicenter study. Brachytherapy. 2017;16(6):1184-91. 45. Serban M, Kirisits C, Pötter R, et al. Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy. Radiother Oncol. 2018;129(3):567-74. 46. Westerveld H, de Leeuw A, Kirchheiner K, et al. Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients. Radiother Oncol. 2016;120(3):420-7. 47. Kirisits C, Siebert FA, Baltas D, et al. Accuracy of volume and DVH parameters determined with different brachytherapy treatment planning systems. Radiother Oncol. 2007;84(3):290-7. 48. De Brabandere M, Mousa AG, Nulens A, et al. Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma. Radiother Oncol. 2008;88(2):217-26. 49. Lindegaard JC, Tanderup K, Nielsen SK, et al. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(3):756-64. 50. Chargari C, Magné N, Dumas I, et al. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys. 2009;74(1):133-9. 51. Rao BS, Das P, Subramanian BV, et al. A Comparative Analysis of Two Different Dose Fractionation Regimens of High Dose Rate Intracavitary Brachytherapy in Treatment of Carcinoma of Uterine Cervix: A Prospective Randomized Study. J Clin Diagn Res. 2017;11(4):Xc06-xc10. 52. Kirisits C, Lang S, Dimopoulos J, et al. Uncertainties when using only one MRI based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer. Radiother Oncol. 2006;81(3):269-75. 53. Fonseca GP, Johansen JG, Smith RL, et al. In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice. Phys Imaging Radiat Oncol. 2020;16:1-11. 54. Tan LT, Potter R, Sturdza A, et al. Change in Patterns of Failure After Image Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. Int J Radiat Oncol Biol Phys. 2019;104(4):895-902. 55. Kirchheiner K, Potter R, Tanderup K, et al. Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. Int J Radiat Oncol Biol Phys. 2016;94(5):1088-98. 56. Wiltink LM, King M, Müller F, et al. A systematic review of the impact of contemporary treatment modalities for cervical cancer on women's self-reported health-related quality of life. Support Care Cancer. 2020;28(10):4627-44. 57. Fletcher GH. Textbook of radiotherapy: Lea & Febiger; 1973. 58. Jampolis S, Andras EJ, Fletcher GH. Analysis of sites and causes of failures of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology. 1975;115(3):681-5. 59. Horiot JC, Pigneux J, Pourquier H, et al. Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: a French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys. 1988;14(4):605-11. 60. Perez CA, Grigsby PW, Chao KS, et al. Tumor size, irradiation dose, and long term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys. 1998;41(2):307-17.

61. Vale C, Tierney JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802-12. 62. Sturdza A, Potter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120(3):428-33. 63. Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. The Lancet Oncology. 2021;22(4):538-47. 64. Sturdza AE, Poetter R, Kossmeier M, et al. Nomogram predicting overall survival in locally advanced cervical cancer patients treated by radio-chemotherapy including image guided brachytherapy: a Retro-EMBRACE study. Int J Radiat Oncol Biol Phys. 2021. 65. Mayr NA, Taoka T, Yuh WT, et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002;52(1):14-22. 66. Oh D, Lee JE, Huh SJ, et al. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013;87(3):549-54. 67. Schmid MP, Lindegaard JC, Mahantshetty U, et al. Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. J Clin Oncol. 2023:Jco2201096. 68. Kang S, Nam BH, Park JY, et al. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study. J Clin Oncol. 2012;30(19):2369-74. 69. Polterauer S, Grimm C, Hofstetter G, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer. 2012;107(6):918 24. 70. Rose PG, Java J, Whitney CW, et al. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. J Clin Oncol. 2015;33(19):2136-42. 71. Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol. 2016;120(3):434-40. 72. 72. Mahantshetty U, Sturdza A, Naga Ch P, et al. Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome. Radiother Oncol. 2019;141:123-9. 73. Kirchheiner K, Nout RA, Tanderup K, et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys. 2014;89(1):88-95. 74. Mazeron R, Fokdal LU, Kirchheiner K, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016;120(3):412-9. 75. Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018;127(3):423-30. 76. Jensen NBK, Pötter R, Kirchheiner K, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018;127(3):431-9. 77. Fokdal L, Tanderup K, Potter R, et al. Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. Int J Radiat Oncol Biol Phys. 2019;103(4):887-94. 78. Vittrup AS, Kirchheiner K, Pötter R, et al. Overall Severe Morbidity After Chemo-Radiation Therapy and Magnetic Resonance Imaging-Guided